Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood tests could replace risky biopsies for transplant patients

NCT ID NCT04855422

Summary

This study is testing two blood tests (AlloSure and AlloMap) to see if they can detect organ rejection in people who have received both a kidney and pancreas transplant. The goal is to find a safer, non-invasive way to monitor transplant health instead of using risky organ biopsies. Researchers will follow 42 transplant patients to see if these blood tests can accurately spot early signs that either organ is being rejected by the body's immune system.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSPLANT; COMPLICATION, REJECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Montefiore Medical Center

    The Bronx, New York, 10461, United States

Conditions

Explore the condition pages connected to this study.